

A BS: 3291.7



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/063,559	05/02/2002	David C. Kulp	3291.7

22886
AFFYMETRIX, INC
ATTN: CHIEF IP COUNSEL, LEGAL DEPT.
3380 CENTRAL EXPRESSWAY
SANTA CLARA, CA 95051

CONFIRMATION NO. 9768

FORMALITIES LETTER



OC000000008103206

#3

Date Mailed: 05/14/2002


NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).


- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov



A copy of this notice **MUST** be returned with the reply.



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

ME



07-15-02

03C046
BOX/Seg

Attorney Docket 3291.7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DAVID C. KULP et al.
Serial No.: 10/063,559
Filed : May 2, 2002

Examiner : TBA
Art Unit : TBA

Title: Method, System, and Computer Software for Providing a Genomic Web Portal

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

TRANSMITTAL OF SEQUENCE LISTING

In response to the Communication mailed on May 14, 2002, I am transmitting herewith, under 37 C.F.R. §1.821, a Sequence Listing (printed) and a Sequence Listing in a computer readable form.

Applicant's attorney attests that the information in the "Sequence Listing" is identical to that which is in computer readable form, as required under 37 C.F.R. §1.821(e), §1.821(f), §1.821(g), §1.825(b), or §1.825(d). This submission introduces no new matter, since the enclosed sequence is identical to the sequence submitted originally in this patent application.

Please charge any fees or apply credits to the Deposit Account No. 01-0431.

Respectfully submitted,

 July 12, 2002
Alan B. Sherr, Reg. No. 42,147

CERTIFICATE OF MAILING UNDER 37 CFR §110(a)

The undersigned hereby certifies that this document is being placed in the U. S. Postal Service as Express Mail No. EL326366982US in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

July 12, 2002


Gilda T. Carr